CANCER CENTER CALGB PARTICIPATION

癌症中心 CALGB 参与

• 批准号: 6173297
• 负责人: HYMAN MUSS
• 金额: $ 11.23万
• 依托单位: UNIVERSITY OF VERMONT & ST AGRIC COLLEGE
• 依托单位国家: 美国
• 财政年份: 1998
• 资助国家: 美国
• 起止时间: 1998-04-20 至 2003-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6173297
• 关键词: AIDS related neoplasm /cancer; aging; antineoplastics; bone marrow transplantation; breast neoplasms; cancer prevention; cancer registry /resource; carmustine; chemoprevention; cis platinum compound; clinical research; clinical trials; combination cancer therapy; combination chemotherapy; cooperative study; cyclophosphamide; doxorubicin; drug resistance; finasteride; fluorouracil; gastrointestinal neoplasms; health care cost /financing; hormone therapy; human genetic material tag; human subject; human therapy evaluation; interleukin 2; leucovorin; leukemia; lymphoma; melanoma; neoplasm /cancer chemotherapy; neoplasm /cancer diagnosis; neoplasm /cancer epidemiology; neoplasm /cancer genetics; neoplasm /cancer immunotherapy; neoplasm /cancer radiation therapy; neoplasm /cancer surgery; neoplasm /cancer vaccine; oncology nursing; paclitaxel; pathology; prostate neoplasms; psychology; quality of life; respiratory neoplasm; tamoxifen; tissue resource /registry; weight loss

DESCRIPTION (adapted from the applicant's abstract): The Vermont Cancer Center (VCC), an NCI designated Comprehensive Cancer Center, joined the CALGB in 1995. In that short time the VCC has made significant headway in becoming a major participant in CALGB activities. Eight VCC members have made major commitments to supporting CALGB efforts. Dr. Hyman Muss continues to be extremely active in CALGB and serves as the Co-Chair of the Working Group for the Elderly and the Vice Chair of the Breast Cancer Committee, in addition to chairing two CALGB protocols (8869 and 9670). Dr. Steven Grunberg, a member of the Clinical Economics Committee, is currently developing a clinical protocol that will compare cost with symptom control for antiemetics. Dr. David Krag is an active member of the Breast Core Committee and is helping CALBG develop a protocol for sentinel node staging for women with early stage breast cancer. Dr. Seth Harlow will assume Dr. Krag's role as member of the Surgery Committee. Dr. Donald Weaver participates extensively in pathology group activities and has a major interest in breast cancer. Drs. Michael Cooper, Barbara Grant, and Richard Branda have major interest in urologic cancer, leukemia and lymphoma, and nutrition and cancer, respectively, and have developed concepts for CALGB clinical investigations. The development of multidisciplinary, disease-site oriented, affinity groups within our Center has established major liaisons between laboratory and clinical scientists. This will strengthen our institutional commitment to the group and allow VCC members to develop innovative companion trials for the CALGB. Recently, Drs. Grant and Branda presented two concepts-one related to assessing the importance of folate status on chemotherapy toxicity in women with early breast cancer, and a second that utilizes a novel reporter gene (hprt) to monitor and possibly define women with early stage breast cancer who might be at high risk for developing secondary acute nonlymphocytic leukemia. Drs. Weaver and other VCC scientists are drafting a concept that will explore the role of erbB-2 associated signaling proteins as mediators of apoptosis for women with early stage breast cancer treated with anthracyclines (CALGB 8541). We anticipate a major increase in accrual in the next year. The Green Mountain Oncology Group (CCOP) selected the VCC as its research base beginning in April, 1997. In one month they have entered 10 patients on CALGB protocols. Two new faculty will join the VCC this summer who have major interests in genetics and high-dose therapy; it is anticipated they will be active in CALGB activities. Also, we are developing a major outreach program and expect to add several affiliates with interest in clinical trials. In addition, we have developed a high-dose chemotherapy autologous stem cell support program and expect to become a CALGB Transplant Center by the start of the next funding period.

描述（改编自申请人的摘要）：佛蒙特州癌症 中心（VCC），一个NCI指定的综合癌症中心，加入了 1995年的CALGB。 在这么短的时间内，VCC在以下方面取得了重大进展： 成为CALGB活动的主要参与者。 八名VCC成员 作出重大承诺，支持CALGB的努力。 海曼·穆斯博士 继续在CALGB中非常活跃，并担任 老年人工作组和乳腺癌委员会副主席 委员会，此外还主持两个CALGB议定书（8869和9670）。 博士 Steven Grunberg是临床经济学委员会的成员， 制定一项临床方案，将成本与症状控制进行比较 止吐药 大卫·克拉格医生是乳腺癌核心组织的活跃成员 委员会，并正在帮助CALBG制定一项协议，前哨淋巴结分期 对于早期乳腺癌的女性。 塞思·哈洛博士将承担博士。 Krag作为外科委员会成员的角色 唐纳德·韦弗博士 广泛参与病理学小组活动，并有一个主要的 对乳腺癌感兴趣。 迈克尔库珀博士芭芭拉格兰特和理查德 布兰达对泌尿系统癌症、白血病和淋巴瘤很感兴趣， 营养和癌症，分别，并制定了概念CALGB 临床研究。 多学科的发展，疾病部位 在我们中心内的面向，亲和团体建立了主要的联络 在实验室和临床科学家之间。 这将加强我们 对集团的机构承诺，并允许VCC成员发展 CALGB的创新伴随试验。 最近格兰特博士和布兰达 提出了两个概念，一个是关于评估叶酸的重要性， 早期乳腺癌化疗毒副反应现状及对策 第二种是利用新的报告基因（HPRT）来监测， 定义患有早期乳腺癌的女性， 继发性急性非淋巴细胞白血病 Dr. Weaver及其他 VCC科学家正在起草一个概念，将探讨erbB-2的作用 相关信号蛋白作为早期乳腺癌妇女细胞凋亡的介质 用蒽环类药物治疗的晚期乳腺癌（CALGB 8541）。 我们预计 下一年的应计利润大幅增加。 绿色山肿瘤学 1997年4月，CCOP集团选择VCC作为其研究基地。 在一个月内，他们已经在CALGB协议上输入了10名患者。 两个新 今年夏天，对遗传学有重大兴趣的教师将加入VCC 和高剂量治疗;预计它们将在CALGB中发挥作用 活动 此外，我们正在制定一项重大的推广计划，并希望 增加几个对临床试验感兴趣的附属机构。 另外我们 开发了一种高剂量化疗自体干细胞支持计划， 并有望在明年年初成为CALGB移植中心 融资期。